Novavax to Highlight RSV Program Data at Two Upcoming Meetings
GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.
Oral presentation details are as follows:
| IDWeek 2018 Meeting | ||
| Title: | Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants | |
| Presenter: | Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc. | |
| Session: | 213. Late Breaker Oral Abstracts: Influenza and Vaccines | |
| Date and Time: | Saturday, October 6, 11:20 a.m. P.T. | |
| Location: | Moscone Convention Center S 152-154 | |
| 11th International Respiratory Syncytial Virus Symposium | ||
| Title: | Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant | |
| Presenter: | Vivek Shinde, M.D., M.P.H., Executive Director, Clinical Development, Novavax, Inc. | |
| Session: | 5. Advancements in RSV Vaccines | |
| Date and Time: | Thursday, November 1, 4:45 p.m. – 6:15 p.m. E.T. | |
| Location: | Omni Grove Park Inn | |
| Title: | Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants | |
| Presenter: | Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc. | |
| Session: | 12. Maternal Immunity & Maternal Vaccination | |
| Date: | Saturday, November 3, 3:00 p.m. – 4:30 p.m. E.T. | |
| Location: | Omni Grove Park Inn | |
Poster presentations for the 11th International Respiratory Syncytial Virus Symposium will occur on Thursday, November 1, 11:30 a.m. – 12:30 p.m. E.T. and on Friday, November 2, 8:30 p.m. – 10:00 p.m. E.T. at the Omni Grove Park Inn.
| Title: | Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization | |
| Presenter: | Yen-Huei Lin, Ph.D., Senior Director, Formulation and Drug Product Development, Novavax, Inc. | |
| Title: | Binding Kinetics of RSVF Prefusogenic Vaccine to Palivizumab and Serum Polyclonal Antibody | |
| Presenter: | Hanxin Lu, Ph.D., Principal Scientist, Novavax, Inc. | |
| Title: | In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine | |
| Presenter: | Ernest Maynard, Ph.D., Principal Scientist, Analystical Development, Novavax, Inc. | |
| Title: | Antigenic Characterization Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats | |
| Presenter: | Nita Patel, Director, Antibody Discovery, Vaccine Development Novavax, Inc. | |
| Title: | Respiratory Syncytial Virus (RSV) Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection | |
| Presenter: | Gale Smith, Ph.D., Vice President, Vaccine Development, Novavax, Inc. |
About Novavax
Novavax, Inc. (Nasdaq:) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit and connect with us on and .
Contacts:
Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
240-268-2000
Westwicke Partners
John Woolford
443-213-0506
Media
Sam Brown
Mike Beyer
312-961-2502
